Knowledge, Attitude &Practice on Human Papilloma Virus Vaccination Among Healthcare Providers and General Population

• Cervical cancer mortality rates in Egypt are also relatively high, with an age-standardized mortality rate of around 3.2 per 100,000 women.

Risk Factors and Epidemiology:

• The primary risk factor for cervical cancer in Egypt is persistent infection with high-risk strains of the human papillomavirus (HPV), particularly HPV 16 and 18.
• Other risk factors include early age of first sexual intercourse, multiple sexual partners, high parity, smoking, and lack of regular cervical cancer screening.
• Socioeconomic factors, such as low education levels and limited access to healthcare services, also contribute to the cervical cancer burden in Egypt.
• Cervical cancer disproportionately affects women in rural and disadvantaged areas, where screening and preventive services are less accessible.

Screening and Prevention Efforts:

• Cervical cancer screening through Pap smears or HPV testing is the primary method for early detection and prevention of the disease.
• However, cervical cancer screening coverage in Egypt remains low, with only around 10-20% of eligible women being regularly screened.
• The Egyptian Ministry of Health and Population has implemented various initiatives to improve cervical cancer screening and awareness, but more efforts are needed to reach underserved populations.
• The introduction and widespread uptake of the HPV vaccine could significantly reduce the burden of cervical cancer in Egypt, but vaccine coverage remains suboptimal.
• Cervical cancer is a significant public health concern, as it is the fourth most common cancer in women worldwide, with a high mortality rate, especially in developing countries.
• Early detection through regular cervical cancer screening (e.g., Pap smears) and treatment of precancerous lesions can effectively prevent the development of cervical cancer.

Role of the HPV Vaccine:

• The HPV vaccine is a highly effective way to prevent cervical cancer and other HPV-related diseases, such as anal, penile, and oropharyngeal cancers.
• The vaccine targets the HPV strains (primarily HPV 16 and 18) that are responsible for approximately 70% of cervical cancer cases globally.
• The HPV vaccine is recommended for both girls and boys, typically starting at 11-12 years of age, as it is most effective when administered before the onset of sexual activity and potential HPV exposure.
• Widespread HPV vaccination, coupled with regular cervical cancer screening, has the potential to significantly reduce the burden of cervical cancer worldwide.

Importance of a KAP Questionnaire in Egypt:

• In Egypt, cervical cancer is the second most common cancer among women, and HPV infection is a major risk factor.
• However, HPV vaccination rates in Egypt remain relatively low, indicating a need to better understand the factors that influence vaccination uptake in the country.
• A KAP questionnaire can provide valuable insights into:
• The level of awareness and knowledge about cervical cancer and the HPV vaccine among the Egyptian population.
• Attitudes, beliefs, and misconceptions that may be hindering or promoting HPV vaccination.
• Current vaccination practices and barriers to accessing the vaccine.
• This information can then be used to develop targeted educational campaigns, address misconceptions, and implement strategies to improve HPV vaccination coverage in Egypt.
• By understanding the KAP of HPV vaccination, policymakers and healthcare providers can work to increase cervical cancer prevention efforts and improve the overall public health outcomes in the country.